PDCD1 and neoplasm: et al. studied the expression of LAG-3 on tumor-infiltrating lymphocytes (TILs) in several syngeneic mouse cancer models and showed that tumors harboring LAG-3-expressing TILs benefit from a combination therapy of PD-1/LAG-3 blocking Abs [92,93].